Agency Information Collection Activities; Proposed Collection; Comment Request; Electronic Submission of Food and Drug Administration Adverse Event Reports and Other Safety Information Using the Electronic Submission Gateway and the Safety Reporting Portal, 56847-56851 [2012-22659]

Download as PDF Federal Register / Vol. 77, No. 179 / Friday, September 14, 2012 / Notices Clinical Laboratory Improvement Amendments Waiver Applications— (OMB Control Number 0910–0598)— Extension Congress passed the Clinical Laboratory Improvement Amendments (CLIA) (Pub. L. 100–578) in 1988 to establish quality standards for all laboratory testing. The purpose was to ensure the accuracy, reliability, and timeliness of patient test results regardless of where the test took place. CLIA requires that clinical laboratories obtain a certificate from the Secretary of Health and Human Services (the Secretary), before accepting materials derived from the human body for laboratory tests (42 U.S.C. 263a(b)). Laboratories that perform only tests that are ‘‘simple’’ and that have an ‘‘insignificant risk of an erroneous result’’ may obtain a certificate of waiver (42 U.S.C. 263a(d)(2)). The Secretary has delegated to FDA the authority to determine whether particular tests (waived tests) are ‘‘simple’’ and have ‘‘an insignificant risk of an erroneous result’’ under CLIA (69 FR 22849, April 27, 2004). On January 30, 2008, FDA published a guidance document entitled ‘‘Guidance for Industry and FDA Staff: Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices’’ (http://www.fda.gov/Medical Devices/DeviceRegulationandGuidance/ GuidanceDocuments/ucm079632.htm). This guidance document describes recommendations for device manufacturers submitting to FDA an application for determination that a cleared or approved device meets this CLIA standard (CLIA waiver application). The guidance recommends that CLIA waiver applications include a description of the features of the device that make it ‘‘simple’’; a report describing a hazard analysis that identifies potential sources of error, including a summary of the design and results of flex studies and conclusions drawn from the flex studies; a description of fail-safe and failure alert mechanisms and a description of the studies validating these mechanisms; a description of clinical tests that demonstrate the accuracy of the test in the hands of intended operators; and statistical analyses of clinical study results. The total number of reporting and recordkeeping hours is 143,200 hours. 56847 FDA bases the burden on an Agency analysis of premarket submissions with clinical trials similar to the waived laboratory tests. Based on previous years’ experience with CLIA waiver applications, FDA expects 40 manufacturers to submit one CLIA waiver application per year. The time required to prepare and submit a waiver application, including the time needed to assemble supporting data, averages 780 hours per waiver application for a total of 31,200 hours for reporting. Based on previous years’ experience with CLIA waiver applications, FDA expects that each manufacturer will spend 2,800 hours creating and maintaining the record for a total of 112,000 hours. The total operating and maintenance cost associated with the waiver application is estimated at $66,200. The cost consists of specimen collection for the clinical study (estimated $23,500); laboratory supplies, reference testing and study oversight (estimated $26,700); shipping and office supplies (estimated $6,000); and educational materials, including quick reference instructions (estimated $10,000). FDA estimates the burden of this collection of information as follows: TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1 Activity Number of respondents Number of responses per respondent Total annual responses Average burden per response Total hours Total operating and maintenance costs CLIA waiver application ........................... 40 1 40 780 31,200 $66,200 1 There are no capital costs associated with this collection of information. TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN Activity Number of recordkeepers Number of records per recordkeeper Total annual records Average burden per recordkeeping Total hours CLIA waiver records .............................. 40 1 40 2,800 112,000 Dated: August 30, 2012. Leslie Kux, Assistant Commissioner for Policy. [FR Doc. 2012–22660 Filed 9–13–12; 8:45 am] Food and Drug Administration [Docket No. FDA–2012–N–0921] BILLING CODE 4160–01–P mstockstill on DSK4VPTVN1PROD with NOTICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency Information Collection Activities; Proposed Collection; Comment Request; Electronic Submission of Food and Drug Administration Adverse Event Reports and Other Safety Information Using the Electronic Submission Gateway and the Safety Reporting Portal AGENCY: Food and Drug Administration, HHS. ACTION: VerDate Mar<15>2010 16:39 Sep 13, 2012 Jkt 226001 PO 00000 Notice. Frm 00040 Fmt 4703 Sfmt 4703 The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the use of the FDA Electronic Submission Gateway (ESG) and the Safety Reporting Portal (the SRP) to collect adverse event reports and other SUMMARY: E:\FR\FM\14SEN1.SGM 14SEN1 56848 Federal Register / Vol. 77, No. 179 / Friday, September 14, 2012 / Notices safety information for FDA-regulated products. when appropriate, and other forms of information technology. Submit either electronic or written comments on the collection of information by November 13, 2012. ADDRESSES: Submit electronic comments on the collection of information to http:// www.regulations.gov. Submit written comments on the collection of information to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50– 400T, Rockville, MD 20850, domini.bean@fda.hhs.gov. II. Electronic Submission of Food and Drug Administration Adverse Event Reports and Other Safety Information Using the Electronic Submission Gateway and the Safety Reporting Portal—21 CFR 310.305, 314.80, 314.98, 314.540, 514.80, 600.80, 1271.350 and Part 803 (OMB Control Number 0910– 0645)—Revision The SRP (formerly referred to as the MedWatchPlus Portal and Rational Questionnaire) and the ESG are the Agency’s electronic systems for collecting, submitting, and processing adverse event reports and other safety information for FDA-regulated products. To ensure the safety and identify any risks, harms, or other dangers to health for all FDA-regulated human and animal products, the Agency needs to be informed whenever an adverse event, product quality problem, or product use error occurs. This risk identification process is the first necessary step that allows the Agency to gather the information necessary to be able to evaluate the risk associated with the product and take whatever action is necessary to mitigate or eliminate the public’s exposure to the risk. Some adverse event reports are required to be submitted to FDA (mandatory reporting) and some adverse event reports are submitted voluntarily (voluntary reporting). Requirements regarding mandatory reporting of adverse events or product problems have been codified in 21 CFR parts 310, 314, 514, 600, 803 and 1271, specifically §§ 310.305, 314.80, 314.98, 314.540, 514.80, 600.80, 803.30, 803.40, 803.50, 803.53, 803.56 and 1271.350(a) (21 CFR 310.305, 314.80, 314.98, 314.540, 514.80, 600.80, 803.30, 803.40, 803.50, 803.53, 803.56 and 1271.350(a)). Many of the adverse event reports submitted to FDA are currently filed in paper format using FDA Forms FDA 3500, 3500A, 1932, and 1932a, approved under OMB control numbers 0910–0284 and 0910–0291. This notice solicits comments on adverse event reports filed electronically via the SRP and the ESG, approved under OMB control number 0910–0645. DATES: SUPPLEMENTARY INFORMATION: mstockstill on DSK4VPTVN1PROD with NOTICES I. Background Under the PRA (44 U.S.C. 3501– 3520), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ‘‘Collection of information’’ is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document. With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA’s functions, including whether the information will have practical utility; (2) the accuracy of FDA’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, VerDate Mar<15>2010 16:39 Sep 13, 2012 Jkt 226001 III. The FDA Safety Reporting Portal Rational Questionnaires FDA currently has OMB approval to receive three types of adverse event reports electronically via the SRP using rational questionnaires. In this notice, FDA seeks comments on the extension of OMB approval for the existing three rational questionnaires, as well as comments on a proposed fourth rational PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 questionnaire that will be used for a new safety reporting program being launched by the Center for Tobacco Products (CTP). A. Reportable Food Registry Reports The Food and Drug Administration Amendments Act of 2007 (Pub. L. 110– 085) (FDAAA) amended the Federal Food, Drug, and Cosmetic Act (the FD&C Act) by creating a new section 417 (21 U.S.C. 350f), Reportable Food Registry (RFR or the Registry). Section 417 of the FD&C Act defines ‘‘reportable food’’ as an ‘‘article of food (other than infant formula or dietary supplements) for which there is a reasonable probability that the use of, or exposure to, such article of food will cause serious adverse health consequences or death to humans or animals.’’ (See section 417(a)(2) of the FD&C Act). The Secretary of Health and Human Services (the Secretary) has delegated to the Commissioner of FDA the responsibility for administering the FD&C Act, including section 417. To further the development of the RFR, section 417 of the FD&C Act required FDA to establish an electronic portal by which instances of reportable food (‘‘RFR reports’’) must be submitted to FDA by responsible parties and may be submitted by public health officials. A ‘‘responsible party’’ is the person who submits the registration under section 415(a) of the FD&C Act (21 U.S.C. 350d) for a food facility that is required to register under section 415(a), at which such article of food is manufactured, processed, packed, or held. The RFR electronic portal was established in 2009 as part of the MedWatchPlus Portal, now the SRP, and approved under OMB control number 0910–0645. The Congressionally identified purpose of the RFR is to provide ‘‘a reliable mechanism to track patterns of adulteration in food [which] would support efforts by the Food and Drug Administration to target limited inspection resources to protect the public health’’ (121 Stat. 965). The RFR reports are designed to enable FDA to quickly identify, track, and remove from commerce an article of food (other than infant formula and dietary supplements) for which there is a reasonable probability that the use of, or exposure to, such article of food will cause serious adverse health consequences or death to humans or animals. FDA uses the information collected to help ensure that such products are quickly and efficiently removed from the market to prevent foodborne illnesses. On January 4, 2011, the President signed into law the FDA Food Safety Modernization Act (Pub. L. 111–353) E:\FR\FM\14SEN1.SGM 14SEN1 Federal Register / Vol. 77, No. 179 / Friday, September 14, 2012 / Notices (the legislation or FSMA). Section 211 of the legislation amended section 417 of the FD&C Act to require FDA to collect additional information in the Agency’s RFR reports: (1) A description of the article of food; (2) Affected product identification codes, such as Universal Product Code, Stock Keeping Unit, or lot or batch numbers sufficient for the consumer to identify the article of food; (3) Contact information for the responsible party; and (4) Any other information the Secretary determines is necessary to enable a consumer to accurately identify whether such consumer is in possession of the reportable food. Section 211 of FSMA also amended section 417 of the FD&C Act to require FDA to generate one-page notices from RFR reports to post on www.fda.gov for grocery stores to display to consumers when a reportable food has been sold. The amendment made by section 211 of FSMA took effect June 4, 2012, 18 months after the date of enactment. To comply with this statutory deadline, FDA initially obtained OMB approval of 56849 the additional collection of information requirements under the emergency processing provisions of the PRA under OMB control number 0910–0709. The new data improves the RFR’s effectiveness in carrying out its purpose of tracking patterns of adulteration in food and supporting FDA’s efforts to target limited inspection resources to protect the public health. Table 1 of this document, entitled ‘‘New Data Elements for RFR Reports,’’ presents the new data elements aded by FDA to RFR Reports on June 4, 2012. TABLE 1—NEW DATA ELEMENTS FOR RFR REPORTS Field text Mandatory or optional input Reason this food is reportable (agent) ............................. What did your investigation identify as the root cause of the problem (if you were required to conduct an investigation under section 417(d)(1)(B) of the FD&C Act)? How did you determine which products/lots/batches were affected? To the best of your knowledge, has all of the reportable food been removed from commerce? What corrective actions have been taken to prevent future occurrences? Product Commodity Type ................................................. Manufacturing/Production Date(s) .................................... Use-by dates, if any, or approximate Shelf Life ............... Was product treated to reduce microorganisms .............. Microbial Reduction Treatment Details ............................. Mandatory .......................... Mandatory .......................... Section 417(e)(4) of the FD&C Act. Section 417(e)(5) of the FD&C Act. Mandatory .......................... Section 417(e)(4) and (5) of the FD&C Act. Mandatory .......................... Section 417(e)(6) of the FD&C Act. Mandatory Mandatory Mandatory Mandatory Mandatory Is a Bacterial Isolate Available for collection? Mandatory (but conditional) Animal Species Intended for ............................................ Life Stage of Animal Intended for ..................................... Have you notified all immediate previous sources of this reportable food? Have you notified all immediate subsequent recipients of this reportable food? Mandatory .......................... Mandatory .......................... Optional .............................. In this request for extension of OMB approval, FDA is combining the burden hours associated with OMB control number 0910–0709 with the burden hours approved under this OMB control number (0910–0645). mstockstill on DSK4VPTVN1PROD with NOTICES B. Reports Concerning Experience With Approved New Animal Drugs Section 512(l) of the FD&C Act (21 U.S.C. 360b(l)) and § 514.80(b) of FDA’s regulations (21 CFR 514.80) require applicants of approved new animal drug applications (NADAs) and approved abbreviated new animal drug applications (ANADAs) to report adverse drug experiences and product/ manufacturing defects. This continuous monitoring of approved NADAs and ANADAs affords the primary means by which FDA obtains information regarding potential problems with the safety and efficacy of VerDate Mar<15>2010 16:39 Sep 13, 2012 Jkt 226001 Authority if mandatory Optional. ............................. .......................... .......................... .......................... (but conditional) (but conditional) Mandatory .......................... Section 417(e)(3) of the FD&C Act. Section 417(e)(3) and (4) of the FD&C Act. Section 417(e)(7) of the FD&C Act. Section 417(e)(3) and (4) of the FD&C Act. Section 417(e)(3) and (4) of the FD&C Act (Conditional for microbial hazards only and only after ‘‘yes’’ answer to ‘‘was product treated to reduce microorganisms?’’) Section 417(e)(4) of the FD&C Act (Conditional for microbial hazards only.) Section 417(e)(3) and (4) of the FD&C Act. Section 417(e)(3) and (4) of the FD&C Act. Section 417(e)(6) of the FD&C Act. marketed approved new animal drugs as well as potential product/manufacturing problems. Post-approval marketing surveillance is important because data previously submitted to FDA may no longer be adequate, as animal drug effects can change over time and less apparent effects may take years to manifest. If an applicant must report adverse drug experiences and product/ manufacturing defects and chooses to do so using the Agency’s paper forms, the applicant is required to use Form FDA 1932, ‘‘Veterinary Adverse Drug Reaction, Lack of Effectiveness, Product Defect Report.’’ Periodic drug experience reports and special drug experience reports must be accompanied by a completed Form FDA 2301, ‘‘Transmittal of Periodic Reports and Promotional Material for New Animal Drugs’’ (see § 514.80(d)). Form PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 FDA 1932a, ‘‘Veterinary Adverse Drug Reaction, Lack of Effectiveness or Product Defect Report’’ allows for voluntary reporting of adverse drug experiences or product/manufacturing defects. Collection of information using existing paper forms FDA 2301, 1932, and 1932a is approved under OMB control number 0910–0284. Alternatively, an applicant may choose to report adverse drug experiences and product/manufacturing defects electronically. Collection of this information electronically was approved in 2010 under OMB control number 0910–0645. The electronic submission data elements to report adverse drug experiences and product/manufacturing defects electronically remain unchanged in this request for extension of OMB approval. E:\FR\FM\14SEN1.SGM 14SEN1 56850 Federal Register / Vol. 77, No. 179 / Friday, September 14, 2012 / Notices C. Pet Food Early Warning System Section 1002(b) of FDAAA directed the Secretary to establish an early warning and surveillance system to identify adulteration of the pet food supply and outbreaks of illness associated with pet food. As part of the effort to fulfill that directive, the Secretary tasked FDA with developing the instrument that would allow consumers to report voluntarily adverse events associated with pet food. FDA developed the Pet Food Early Warning System rational questionnaire as a user-friendly data collection tool, to make it easy for the public to report a safety problem with pet food. The Pet Food Early Warning System is designed to identify adulteration of the pet food supply and outbreaks of illness associated with pet food to enable FDA to quickly identify, track, and remove from commerce such articles of food. FDA uses the information collected to help ensure that such products are quickly and efficiently removed from the market to prevent foodborne illnesses. In 2010, OMB approved the Pet Food Early Warning System component of the SRP under OMB control number 0910–0645, and FDA launched the rational questionnaire by which consumers may electronically report adverse events associated with pet food. The electronic submission data elements to report adverse events associated with pet food remain unchanged in this request for extension of OMB approval. D. Voluntary Tobacco Product Adverse Event and Product Problem Reports As noted, this notice seeks comments on a proposed fourth rational questionnaire that will be used for a new safety reporting program being launched by the FDA Center for Tobacco Products (CTP) to collect voluntary tobacco product adverse event and product problem reports. FDA has broad legal authority under the FD&C Act to protect the public health. CTP’s mission is to protect Americans from tobacco-related death and disease by regulating the manufacture, distribution, and marketing of tobacco products and by educating the public, especially young people, about tobacco products and the dangers their use poses to themselves and others. The Family Smoking Prevention and Tobacco Control Act of 2009 (Pub. L. 111–31) (Tobacco Control Act) amended the FD&C Act by creating a new section 909 (21 U.S.C. 387i, Records and Reports on Tobacco Products). Section 909(a) of the FD&C Act (21 U.S.C. 387i(a)) authorizes FDA to establish regulations with respect to mandatory adverse event reports associated with the use of a tobacco product. At this time, FDA is proposing to collect voluntary adverse event reports associated with the use of tobacco products from interested parties such as health care providers, researchers, consumers, and other users of tobacco products. Information collected in voluntary adverse event reports will contribute to CTP’s ability to be informed of, and assess the real consequences of, tobacco product use. The need for this collection of information derives from our objective to obtain current, timely, and policyrelevant information to carry out our statutory functions. The FDA Commissioner is authorized to undertake this collection as specified in section 1003(d)(2) of the FD&C Act (21 U.S.C. 393(d)(2)). CTP currently receives adverse event and product problem reports primarily via paper MedWatch forms, approved under OMB control number 0910–0291. MedWatch forms, although recently updated with field labels and descriptions to better clarify for reporters the range of reportable products, including tobacco products, do not specifically include questions relevant for the analysis of adverse events or product problems related to tobacco products. The proposed voluntary tobacco product adverse event and product problem rational questionnaire will include these specific questions. The questionnaire evolved with input from a National Institutes of Health team of human-factors experts, from other regulatory Agencies, and with extensive input from consumer advocacy groups and the general public. FDA is also working with the FDA Internet team to follow the HHS Internet guidelines for Web design. FDA has and will continue to reach out to professional organizations and community interest groups to collect feedback during the user acceptance testing. The rational questionnaire will provide the user with detailed navigation instructions to include dropdown menus, lists of values, controlled vocabularies, and mouse over help where possible. In addition, CTP will issue guidance for the rational questionnaire. Finally, we note that users who are unable to submit reports using the electronic system will still be able to provide their information by paper form (by mail or fax) or telephone. The rational questionnaire will capture tobacco-specific adverse event and product problem information from voluntary reporting entities such as health care providers, researchers, consumers, and other users of tobacco products. To carry out its responsibilities, FDA needs to be informed when an adverse event, product problem, or error with use is suspected or identified. When FDA receives tobacco-specific adverse event and product problem information, it will use the information to assess and evaluate the risk associated with the product, and then FDA will take whatever action is necessary to reduce, mitigate, or eliminate the public’s exposure to the risk through regulatory and public health interventions. IV. Information Collection Burden Estimate Description of respondents: The respondents to this collection of information include all persons submitting mandatory or voluntary adverse event reports electronically to FDA via the ESG or the SRP. FDA estimates the burden of this collection of information as follows: TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN 1 mstockstill on DSK4VPTVN1PROD with NOTICES Activity FDA Form No. Voluntary Adverse Event Report via the SRP (Other than RFR Reports). Mandatory Adverse Event Report via the SRP (Other than RFR Reports). Mandatory Adverse Event Report via the ESG (Gateway-to-Gateway transmission). VerDate Mar<15>2010 16:39 Sep 13, 2012 Jkt 226001 Number of respondents Number of responses per respondent Total annual responses 3800 1,513 1 1,513 3800 636 1 636 3800 1,491,228 1 1,491,228 PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 E:\FR\FM\14SEN1.SGM Average burden per response Total hours 0.6 (36 minutes) 908 1.0 ...................... 636 0.6 (36 minutes) 14SEN1 894,737 56851 Federal Register / Vol. 77, No. 179 / Friday, September 14, 2012 / Notices TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN 1—Continued Activity FDA Form No. Number of respondents Number of responses per respondent Total annual responses Mandatory and Voluntary RFR Reports via the SRP. 3800 1,413 1 1,413 Total ............................................. ........................ ........................ ........................ ........................ 1 mstockstill on DSK4VPTVN1PROD with NOTICES Average burden per response Total hours 0.6 (36 minutes) ............................ 848 897,129 There are no capital costs or operating and maintenance costs associated with this collection of information. The Agency’s estimate of the number of respondents and the total annual responses in table 2, Estimated Annual Reporting Burden, is based primarily on mandatory and voluntary adverse event reports electronically submitted to the Agency. The estimated total annual responses are based on initial reports. Follow-up reports, if any, are not counted as new reports. Based on its experience with adverse event reporting, FDA estimates that it will take a respondent 0.6 hour to submit a voluntary adverse event report via the SRP, 1.0 hour to submit a mandatory adverse event report via the SRP, and 0.6 hour to submit a mandatory adverse event report via the ESG (gateway-togateway transmission). Both mandatory and voluntary RFR reports must be submitted via the SRP. FDA estimates that it will take a respondent 0.6 hour to submit a RFR report, whether the submission is mandatory or voluntary. Voluntary adverse event reports submitted via the SRP (other than RFR Reports) include reports associated with pet food (the Pet Food Early Warning System) and the new tobacco product adverse event and product problem reports. CVM received 845 pet food adverse event reports in 2010; 1,293 reports in 2011; and 471 reports in the first 4 months of 2012; and estimates that for the full 12 months of 2012 it will receive 1,413 reports. Based on this experience, CVM estimates that it will receive, on average, 1,413 pet food reports annually over the next 3 years. CTP estimates that it will receive approximately 100 voluntary tobacco product adverse event and product problem reports annually, after implementation of electronic reporting. CTP received 27 reports in 2010, 30 reports in 2011, and 22 reports in the first half of 2012, and estimates that for the full 12 months of 2012 it will receive over 40 reports. Based on this experience and an expectation that reporting will increase once electronic reporting is launched, CTP estimates that it will receive, on average, 100 voluntary adverse event and product problem reports annually over the next 3 years. Thus, FDA estimates that over VerDate Mar<15>2010 16:39 Sep 13, 2012 Jkt 226001 the next 3 years it will receive annually 1,513 voluntary adverse event reports submitted via the SRP, with a burden of 907.8 hours, rounded to 908 hours, as reported in table 2, row 1 (1,413 + 100 = 1,513). Mandatory adverse event reports submitted via the SRP (other than RFR Reports) include reports of adverse animal drug experiences and product/ manufacturing defects associated with approved NADAs and ANADAs. CVM received 144 such adverse event reports in 2010, 537 reports in 2011, and 212 reports in the first 4 months of 2012, and estimates that for the full 12 months of 2012 it will receive 636 reports. Based on this experience, CVM estimates that it will receive, on average, 636 reports of adverse drug experiences and product/manufacturing defects associated with approved NADAs and ANADAs annually over the next 3 years. Thus, FDA estimates that over the next 3 years it will receive annually 636 mandatory adverse event reports submitted via the SRP, with a burden of 636 hours, as reported in table 2, row 2. Adverse event reports submitted via the ESG include reports of adverse experiences related to drugs, biological products, and medical devices, as well as, adverse animal drug experiences and product/manufacturing defects associated with approved NADAs and ANADAs. FDA received 586,229 such adverse event reports in 2010; 850,161 reports in 2011; and 497,076 reports in the first 4 months of 2012; and estimates that for the full 12 months of 2012 it will receive 1,491,228 reports. Based on this experience, FDA estimates that it will receive, on average, 1,491,228 adverse event reports submitted via the ESG, with a burden of 894,736.8 hours, rounded to 894,737 hours, as reported in table 2, row 3. FDA estimates that over the next 3 years it will receive annually 1,413 mandatory and voluntary RFR Reports submitted via the SRP, as reported in table 2, row 4. CFSAN received 845 such adverse event reports in 2010; 1,293 reports in 2011; and 471 reports in the first 4 months of 2012; and estimates that for the full 12 months of PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 2012 it will receive 1,413 reports. Based on this experience, CFSAN estimates that it will receive, on average, 1,413 mandatory and voluntary RFR Reports submitted via the SRP annually over the next 3 years, with a burden of 847.8 hours, rounded to 848 hours, as reported in table 2, row 4. The burden hours required to complete paper FDA reporting forms (Forms FDA 3500, 3500A, 1932, and 1932a) are reported under OMB control numbers 0910–0284 and 0910–0291. While FDA does not charge for the use of the ESG, FDA requires respondents to obtain a public key infrastructure certificate in order to set up the account. This can be obtained inhouse or outsourced by purchasing a public key certificate that is valid for 1 year to 3 years. The certificate typically costs from $20 to $30. Dated: August 29, 2012. Leslie Kux, Assistant Commissioner for Policy. [FR Doc. 2012–22659 Filed 9–13–12; 8:45 am] BILLING CODE 4160–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2007–D–0369 (formerly Docket 2007D–0168)] Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is announcing the availability of additional draft and revised draft product-specific bioequivalence (BE) recommendations. The recommendations provide productspecific guidance on the design of BE studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance SUMMARY: E:\FR\FM\14SEN1.SGM 14SEN1

Agencies

[Federal Register Volume 77, Number 179 (Friday, September 14, 2012)]
[Notices]
[Pages 56847-56851]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-22659]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2012-N-0921]


Agency Information Collection Activities; Proposed Collection; 
Comment Request; Electronic Submission of Food and Drug Administration 
Adverse Event Reports and Other Safety Information Using the Electronic 
Submission Gateway and the Safety Reporting Portal

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an 
opportunity for public comment on the proposed collection of certain 
information by the Agency. Under the Paperwork Reduction Act of 1995 
(the PRA), Federal Agencies are required to publish notice in the 
Federal Register concerning each proposed collection of information, 
including each proposed extension of an existing collection of 
information, and to allow 60 days for public comment in response to the 
notice. This notice solicits comments on the use of the FDA Electronic 
Submission Gateway (ESG) and the Safety Reporting Portal (the SRP) to 
collect adverse event reports and other

[[Page 56848]]

safety information for FDA-regulated products.

DATES: Submit either electronic or written comments on the collection 
of information by November 13, 2012.

ADDRESSES: Submit electronic comments on the collection of information 
to http://www.regulations.gov. Submit written comments on the 
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
Rockville, MD 20852. All comments should be identified with the docket 
number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Information 
Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400T, 
Rockville, MD 20850, domini.bean@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background

    Under the PRA (44 U.S.C. 3501-3520), Federal Agencies must obtain 
approval from the Office of Management and Budget (OMB) for each 
collection of information they conduct or sponsor. ``Collection of 
information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and 
includes Agency requests or requirements that members of the public 
submit reports, keep records, or provide information to a third party. 
Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires 
Federal Agencies to provide a 60-day notice in the Federal Register 
concerning each proposed collection of information, including each 
proposed extension of an existing collection of information, before 
submitting the collection to OMB for approval. To comply with this 
requirement, FDA is publishing notice of the proposed collection of 
information set forth in this document.
    With respect to the following collection of information, FDA 
invites comments on these topics: (1) Whether the proposed collection 
of information is necessary for the proper performance of FDA's 
functions, including whether the information will have practical 
utility; (2) the accuracy of FDA's estimate of the burden of the 
proposed collection of information, including the validity of the 
methodology and assumptions used; (3) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (4) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques, when 
appropriate, and other forms of information technology.

II. Electronic Submission of Food and Drug Administration Adverse Event 
Reports and Other Safety Information Using the Electronic Submission 
Gateway and the Safety Reporting Portal--21 CFR 310.305, 314.80, 
314.98, 314.540, 514.80, 600.80, 1271.350 and Part 803 (OMB Control 
Number 0910-0645)--Revision

    The SRP (formerly referred to as the MedWatch\Plus\ Portal and 
Rational Questionnaire) and the ESG are the Agency's electronic systems 
for collecting, submitting, and processing adverse event reports and 
other safety information for FDA-regulated products. To ensure the 
safety and identify any risks, harms, or other dangers to health for 
all FDA-regulated human and animal products, the Agency needs to be 
informed whenever an adverse event, product quality problem, or product 
use error occurs. This risk identification process is the first 
necessary step that allows the Agency to gather the information 
necessary to be able to evaluate the risk associated with the product 
and take whatever action is necessary to mitigate or eliminate the 
public's exposure to the risk.
    Some adverse event reports are required to be submitted to FDA 
(mandatory reporting) and some adverse event reports are submitted 
voluntarily (voluntary reporting). Requirements regarding mandatory 
reporting of adverse events or product problems have been codified in 
21 CFR parts 310, 314, 514, 600, 803 and 1271, specifically Sec. Sec.  
310.305, 314.80, 314.98, 314.540, 514.80, 600.80, 803.30, 803.40, 
803.50, 803.53, 803.56 and 1271.350(a) (21 CFR 310.305, 314.80, 314.98, 
314.540, 514.80, 600.80, 803.30, 803.40, 803.50, 803.53, 803.56 and 
1271.350(a)). Many of the adverse event reports submitted to FDA are 
currently filed in paper format using FDA Forms FDA 3500, 3500A, 1932, 
and 1932a, approved under OMB control numbers 0910-0284 and 0910-0291. 
This notice solicits comments on adverse event reports filed 
electronically via the SRP and the ESG, approved under OMB control 
number 0910-0645.

III. The FDA Safety Reporting Portal Rational Questionnaires

    FDA currently has OMB approval to receive three types of adverse 
event reports electronically via the SRP using rational questionnaires. 
In this notice, FDA seeks comments on the extension of OMB approval for 
the existing three rational questionnaires, as well as comments on a 
proposed fourth rational questionnaire that will be used for a new 
safety reporting program being launched by the Center for Tobacco 
Products (CTP).

A. Reportable Food Registry Reports

    The Food and Drug Administration Amendments Act of 2007 (Pub. L. 
110-085) (FDAAA) amended the Federal Food, Drug, and Cosmetic Act (the 
FD&C Act) by creating a new section 417 (21 U.S.C. 350f), Reportable 
Food Registry (RFR or the Registry). Section 417 of the FD&C Act 
defines ``reportable food'' as an ``article of food (other than infant 
formula or dietary supplements) for which there is a reasonable 
probability that the use of, or exposure to, such article of food will 
cause serious adverse health consequences or death to humans or 
animals.'' (See section 417(a)(2) of the FD&C Act). The Secretary of 
Health and Human Services (the Secretary) has delegated to the 
Commissioner of FDA the responsibility for administering the FD&C Act, 
including section 417. To further the development of the RFR, section 
417 of the FD&C Act required FDA to establish an electronic portal by 
which instances of reportable food (``RFR reports'') must be submitted 
to FDA by responsible parties and may be submitted by public health 
officials. A ``responsible party'' is the person who submits the 
registration under section 415(a) of the FD&C Act (21 U.S.C. 350d) for 
a food facility that is required to register under section 415(a), at 
which such article of food is manufactured, processed, packed, or held. 
The RFR electronic portal was established in 2009 as part of the 
MedWatch\Plus\ Portal, now the SRP, and approved under OMB control 
number 0910-0645.
    The Congressionally identified purpose of the RFR is to provide ``a 
reliable mechanism to track patterns of adulteration in food [which] 
would support efforts by the Food and Drug Administration to target 
limited inspection resources to protect the public health'' (121 Stat. 
965). The RFR reports are designed to enable FDA to quickly identify, 
track, and remove from commerce an article of food (other than infant 
formula and dietary supplements) for which there is a reasonable 
probability that the use of, or exposure to, such article of food will 
cause serious adverse health consequences or death to humans or 
animals. FDA uses the information collected to help ensure that such 
products are quickly and efficiently removed from the market to prevent 
foodborne illnesses.
    On January 4, 2011, the President signed into law the FDA Food 
Safety Modernization Act (Pub. L. 111-353)

[[Page 56849]]

(the legislation or FSMA). Section 211 of the legislation amended 
section 417 of the FD&C Act to require FDA to collect additional 
information in the Agency's RFR reports:
    (1) A description of the article of food;
    (2) Affected product identification codes, such as Universal 
Product Code, Stock Keeping Unit, or lot or batch numbers sufficient 
for the consumer to identify the article of food;
    (3) Contact information for the responsible party; and
    (4) Any other information the Secretary determines is necessary to 
enable a consumer to accurately identify whether such consumer is in 
possession of the reportable food.
    Section 211 of FSMA also amended section 417 of the FD&C Act to 
require FDA to generate one-page notices from RFR reports to post on 
www.fda.gov for grocery stores to display to consumers when a 
reportable food has been sold. The amendment made by section 211 of 
FSMA took effect June 4, 2012, 18 months after the date of enactment. 
To comply with this statutory deadline, FDA initially obtained OMB 
approval of the additional collection of information requirements under 
the emergency processing provisions of the PRA under OMB control number 
0910-0709. The new data improves the RFR's effectiveness in carrying 
out its purpose of tracking patterns of adulteration in food and 
supporting FDA's efforts to target limited inspection resources to 
protect the public health.
    Table 1 of this document, entitled ``New Data Elements for RFR 
Reports,'' presents the new data elements aded by FDA to RFR Reports on 
June 4, 2012.

               Table 1--New Data Elements for RFR Reports
------------------------------------------------------------------------
                                   Mandatory or         Authority if
          Field text              optional input         mandatory
------------------------------------------------------------------------
Reason this food is reportable  Mandatory........  Section 417(e)(4) of
 (agent).                                           the FD&C Act.
What did your investigation     Mandatory........  Section 417(e)(5) of
 identify as the root cause of                      the FD&C Act.
 the problem (if you were
 required to conduct an
 investigation under section
 417(d)(1)(B) of the FD&C
 Act)?
How did you determine which     Mandatory........  Section 417(e)(4) and
 products/lots/batches were                         (5) of the FD&C Act.
 affected?
To the best of your knowledge,  Mandatory........  Section 417(e)(6) of
 has all of the reportable                          the FD&C Act.
 food been removed from
 commerce?
What corrective actions have    Optional.........  .....................
 been taken to prevent future
 occurrences?
Product Commodity Type........  Mandatory........  Section 417(e)(3) of
                                                    the FD&C Act.
Manufacturing/Production        Mandatory........  Section 417(e)(3) and
 Date(s).                                           (4) of the FD&C Act.
Use-by dates, if any, or        Mandatory........  Section 417(e)(7) of
 approximate Shelf Life.                            the FD&C Act.
Was product treated to reduce   Mandatory (but     Section 417(e)(3) and
 microorganisms.                 conditional).      (4) of the FD&C Act.
Microbial Reduction Treatment   Mandatory (but     Section 417(e)(3) and
 Details.                        conditional).      (4) of the FD&C Act
                                                    (Conditional for
                                                    microbial hazards
                                                    only and only after
                                                    ``yes'' answer to
                                                    ``was product
                                                    treated to reduce
                                                    microorganisms?'')
Is a Bacterial Isolate          Mandatory (but     Section 417(e)(4) of
 Available for collection?       conditional).      the FD&C Act
                                                    (Conditional for
                                                    microbial hazards
                                                    only.)
Animal Species Intended for...  Mandatory........  Section 417(e)(3) and
                                                    (4) of the FD&C Act.
Life Stage of Animal Intended   Mandatory........  Section 417(e)(3) and
 for.                                               (4) of the FD&C Act.
Have you notified all           Optional.........  .....................
 immediate previous sources of
 this reportable food?
Have you notified all           Mandatory........  Section 417(e)(6) of
 immediate subsequent                               the FD&C Act.
 recipients of this reportable
 food?
------------------------------------------------------------------------

    In this request for extension of OMB approval, FDA is combining the 
burden hours associated with OMB control number 0910-0709 with the 
burden hours approved under this OMB control number (0910-0645).

B. Reports Concerning Experience With Approved New Animal Drugs

    Section 512(l) of the FD&C Act (21 U.S.C. 360b(l)) and Sec.  
514.80(b) of FDA's regulations (21 CFR 514.80) require applicants of 
approved new animal drug applications (NADAs) and approved abbreviated 
new animal drug applications (ANADAs) to report adverse drug 
experiences and product/manufacturing defects.
    This continuous monitoring of approved NADAs and ANADAs affords the 
primary means by which FDA obtains information regarding potential 
problems with the safety and efficacy of marketed approved new animal 
drugs as well as potential product/manufacturing problems. Post-
approval marketing surveillance is important because data previously 
submitted to FDA may no longer be adequate, as animal drug effects can 
change over time and less apparent effects may take years to manifest.
    If an applicant must report adverse drug experiences and product/
manufacturing defects and chooses to do so using the Agency's paper 
forms, the applicant is required to use Form FDA 1932, ``Veterinary 
Adverse Drug Reaction, Lack of Effectiveness, Product Defect Report.'' 
Periodic drug experience reports and special drug experience reports 
must be accompanied by a completed Form FDA 2301, ``Transmittal of 
Periodic Reports and Promotional Material for New Animal Drugs'' (see 
Sec.  514.80(d)). Form FDA 1932a, ``Veterinary Adverse Drug Reaction, 
Lack of Effectiveness or Product Defect Report'' allows for voluntary 
reporting of adverse drug experiences or product/manufacturing defects. 
Collection of information using existing paper forms FDA 2301, 1932, 
and 1932a is approved under OMB control number 0910-0284. 
Alternatively, an applicant may choose to report adverse drug 
experiences and product/manufacturing defects electronically. 
Collection of this information electronically was approved in 2010 
under OMB control number 0910-0645. The electronic submission data 
elements to report adverse drug experiences and product/manufacturing 
defects electronically remain unchanged in this request for extension 
of OMB approval.

[[Page 56850]]

C. Pet Food Early Warning System

    Section 1002(b) of FDAAA directed the Secretary to establish an 
early warning and surveillance system to identify adulteration of the 
pet food supply and outbreaks of illness associated with pet food. As 
part of the effort to fulfill that directive, the Secretary tasked FDA 
with developing the instrument that would allow consumers to report 
voluntarily adverse events associated with pet food.
    FDA developed the Pet Food Early Warning System rational 
questionnaire as a user-friendly data collection tool, to make it easy 
for the public to report a safety problem with pet food. The Pet Food 
Early Warning System is designed to identify adulteration of the pet 
food supply and outbreaks of illness associated with pet food to enable 
FDA to quickly identify, track, and remove from commerce such articles 
of food. FDA uses the information collected to help ensure that such 
products are quickly and efficiently removed from the market to prevent 
foodborne illnesses. In 2010, OMB approved the Pet Food Early Warning 
System component of the SRP under OMB control number 0910-0645, and FDA 
launched the rational questionnaire by which consumers may 
electronically report adverse events associated with pet food. The 
electronic submission data elements to report adverse events associated 
with pet food remain unchanged in this request for extension of OMB 
approval.

D. Voluntary Tobacco Product Adverse Event and Product Problem Reports

    As noted, this notice seeks comments on a proposed fourth rational 
questionnaire that will be used for a new safety reporting program 
being launched by the FDA Center for Tobacco Products (CTP) to collect 
voluntary tobacco product adverse event and product problem reports.
    FDA has broad legal authority under the FD&C Act to protect the 
public health. CTP's mission is to protect Americans from tobacco-
related death and disease by regulating the manufacture, distribution, 
and marketing of tobacco products and by educating the public, 
especially young people, about tobacco products and the dangers their 
use poses to themselves and others. The Family Smoking Prevention and 
Tobacco Control Act of 2009 (Pub. L. 111-31) (Tobacco Control Act) 
amended the FD&C Act by creating a new section 909 (21 U.S.C. 387i, 
Records and Reports on Tobacco Products). Section 909(a) of the FD&C 
Act (21 U.S.C. 387i(a)) authorizes FDA to establish regulations with 
respect to mandatory adverse event reports associated with the use of a 
tobacco product. At this time, FDA is proposing to collect voluntary 
adverse event reports associated with the use of tobacco products from 
interested parties such as health care providers, researchers, 
consumers, and other users of tobacco products. Information collected 
in voluntary adverse event reports will contribute to CTP's ability to 
be informed of, and assess the real consequences of, tobacco product 
use. The need for this collection of information derives from our 
objective to obtain current, timely, and policy-relevant information to 
carry out our statutory functions. The FDA Commissioner is authorized 
to undertake this collection as specified in section 1003(d)(2) of the 
FD&C Act (21 U.S.C. 393(d)(2)).
    CTP currently receives adverse event and product problem reports 
primarily via paper MedWatch forms, approved under OMB control number 
0910-0291. MedWatch forms, although recently updated with field labels 
and descriptions to better clarify for reporters the range of 
reportable products, including tobacco products, do not specifically 
include questions relevant for the analysis of adverse events or 
product problems related to tobacco products. The proposed voluntary 
tobacco product adverse event and product problem rational 
questionnaire will include these specific questions. The questionnaire 
evolved with input from a National Institutes of Health team of human-
factors experts, from other regulatory Agencies, and with extensive 
input from consumer advocacy groups and the general public. FDA is also 
working with the FDA Internet team to follow the HHS Internet 
guidelines for Web design. FDA has and will continue to reach out to 
professional organizations and community interest groups to collect 
feedback during the user acceptance testing. The rational questionnaire 
will provide the user with detailed navigation instructions to include 
drop-down menus, lists of values, controlled vocabularies, and mouse 
over help where possible. In addition, CTP will issue guidance for the 
rational questionnaire. Finally, we note that users who are unable to 
submit reports using the electronic system will still be able to 
provide their information by paper form (by mail or fax) or telephone.
    The rational questionnaire will capture tobacco-specific adverse 
event and product problem information from voluntary reporting entities 
such as health care providers, researchers, consumers, and other users 
of tobacco products. To carry out its responsibilities, FDA needs to be 
informed when an adverse event, product problem, or error with use is 
suspected or identified. When FDA receives tobacco-specific adverse 
event and product problem information, it will use the information to 
assess and evaluate the risk associated with the product, and then FDA 
will take whatever action is necessary to reduce, mitigate, or 
eliminate the public's exposure to the risk through regulatory and 
public health interventions.

IV. Information Collection Burden Estimate

    Description of respondents: The respondents to this collection of 
information include all persons submitting mandatory or voluntary 
adverse event reports electronically to FDA via the ESG or the SRP.
    FDA estimates the burden of this collection of information as 
follows:

                                                     Table 2--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                            Number of
                Activity                  FDA Form No.      Number of     responses per   Total annual     Average burden per response      Total hours
                                                           respondents     respondent       responses
--------------------------------------------------------------------------------------------------------------------------------------------------------
Voluntary Adverse Event Report via the             3800           1,513               1           1,513  0.6 (36 minutes)...............             908
 SRP (Other than RFR Reports).
Mandatory Adverse Event Report via the             3800             636               1             636  1.0............................             636
 SRP (Other than RFR Reports).
Mandatory Adverse Event Report via the             3800       1,491,228               1       1,491,228  0.6 (36 minutes)...............         894,737
 ESG (Gateway-to-Gateway transmission).

[[Page 56851]]

 
Mandatory and Voluntary RFR Reports via            3800           1,413               1           1,413  0.6 (36 minutes)...............             848
 the SRP.
                                        ----------------------------------------------------------------------------------------------------------------
    Total..............................  ..............  ..............  ..............  ..............  ...............................         897,129
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.

    The Agency's estimate of the number of respondents and the total 
annual responses in table 2, Estimated Annual Reporting Burden, is 
based primarily on mandatory and voluntary adverse event reports 
electronically submitted to the Agency. The estimated total annual 
responses are based on initial reports. Follow-up reports, if any, are 
not counted as new reports. Based on its experience with adverse event 
reporting, FDA estimates that it will take a respondent 0.6 hour to 
submit a voluntary adverse event report via the SRP, 1.0 hour to submit 
a mandatory adverse event report via the SRP, and 0.6 hour to submit a 
mandatory adverse event report via the ESG (gateway-to-gateway 
transmission). Both mandatory and voluntary RFR reports must be 
submitted via the SRP. FDA estimates that it will take a respondent 0.6 
hour to submit a RFR report, whether the submission is mandatory or 
voluntary.
    Voluntary adverse event reports submitted via the SRP (other than 
RFR Reports) include reports associated with pet food (the Pet Food 
Early Warning System) and the new tobacco product adverse event and 
product problem reports. CVM received 845 pet food adverse event 
reports in 2010; 1,293 reports in 2011; and 471 reports in the first 4 
months of 2012; and estimates that for the full 12 months of 2012 it 
will receive 1,413 reports. Based on this experience, CVM estimates 
that it will receive, on average, 1,413 pet food reports annually over 
the next 3 years. CTP estimates that it will receive approximately 100 
voluntary tobacco product adverse event and product problem reports 
annually, after implementation of electronic reporting. CTP received 27 
reports in 2010, 30 reports in 2011, and 22 reports in the first half 
of 2012, and estimates that for the full 12 months of 2012 it will 
receive over 40 reports. Based on this experience and an expectation 
that reporting will increase once electronic reporting is launched, CTP 
estimates that it will receive, on average, 100 voluntary adverse event 
and product problem reports annually over the next 3 years. Thus, FDA 
estimates that over the next 3 years it will receive annually 1,513 
voluntary adverse event reports submitted via the SRP, with a burden of 
907.8 hours, rounded to 908 hours, as reported in table 2, row 1 (1,413 
+ 100 = 1,513).
    Mandatory adverse event reports submitted via the SRP (other than 
RFR Reports) include reports of adverse animal drug experiences and 
product/manufacturing defects associated with approved NADAs and 
ANADAs. CVM received 144 such adverse event reports in 2010, 537 
reports in 2011, and 212 reports in the first 4 months of 2012, and 
estimates that for the full 12 months of 2012 it will receive 636 
reports. Based on this experience, CVM estimates that it will receive, 
on average, 636 reports of adverse drug experiences and product/
manufacturing defects associated with approved NADAs and ANADAs 
annually over the next 3 years. Thus, FDA estimates that over the next 
3 years it will receive annually 636 mandatory adverse event reports 
submitted via the SRP, with a burden of 636 hours, as reported in table 
2, row 2.
    Adverse event reports submitted via the ESG include reports of 
adverse experiences related to drugs, biological products, and medical 
devices, as well as, adverse animal drug experiences and product/
manufacturing defects associated with approved NADAs and ANADAs. FDA 
received 586,229 such adverse event reports in 2010; 850,161 reports in 
2011; and 497,076 reports in the first 4 months of 2012; and estimates 
that for the full 12 months of 2012 it will receive 1,491,228 reports. 
Based on this experience, FDA estimates that it will receive, on 
average, 1,491,228 adverse event reports submitted via the ESG, with a 
burden of 894,736.8 hours, rounded to 894,737 hours, as reported in 
table 2, row 3.
    FDA estimates that over the next 3 years it will receive annually 
1,413 mandatory and voluntary RFR Reports submitted via the SRP, as 
reported in table 2, row 4. CFSAN received 845 such adverse event 
reports in 2010; 1,293 reports in 2011; and 471 reports in the first 4 
months of 2012; and estimates that for the full 12 months of 2012 it 
will receive 1,413 reports. Based on this experience, CFSAN estimates 
that it will receive, on average, 1,413 mandatory and voluntary RFR 
Reports submitted via the SRP annually over the next 3 years, with a 
burden of 847.8 hours, rounded to 848 hours, as reported in table 2, 
row 4.
    The burden hours required to complete paper FDA reporting forms 
(Forms FDA 3500, 3500A, 1932, and 1932a) are reported under OMB control 
numbers 0910-0284 and 0910-0291.
    While FDA does not charge for the use of the ESG, FDA requires 
respondents to obtain a public key infrastructure certificate in order 
to set up the account. This can be obtained in-house or outsourced by 
purchasing a public key certificate that is valid for 1 year to 3 
years. The certificate typically costs from $20 to $30.

    Dated: August 29, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2012-22659 Filed 9-13-12; 8:45 am]
BILLING CODE 4160-01-P